ARID4B and breast cancer: Analysis of a pooled breast cancer dataset using GOBO (http://co.bmc.lu.se/gobo/) [16] showed that among the subgroup of patients with ER-positive tumors, the cohort with high expression of ARID4B had significantly reduced DMFS compared to the low or median ARID4B cohorts (Figure 8).